Quince Therapeutics’ lead asset eDSP failed to meet the primary or secondary endpoints in the pivotal NEAT trial.
Venglustat is designed to reduce the toxic buildup, and the new trial showed that a daily dose of the drug achieved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results